ANXA3 and colorectal carcinoma: In the verification phase, six TAAbs, including anti-CKS1B, anti-ACTG1, anti-S100A11, anti-maspin, anti-ANXA3, and anti-eEF2, showed significant differences between CRC patients and NC (all P < 0.05) (Fig. 3a).